Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cholecystectomy & appendectomy cases in West Virginia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 39 | 1,444 | 36% |
| 2020 | 30 | 1,175 | 41% |
| 2021 | 22 | 1,086 |
The highest-volume laparoscopic cases; identifies every active general surgeon. Professional codes (what the surgeon bills): CPT 47562, 47563, 44970, 47600; the hospital bills MS-DRG 417, 418, 419, 338, 339, 340, 397, 398, 399.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in West Virginia; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 8 | 821−8.3%/yr | −8.3%/yr | 4.20.7× | 0% | 620 in 2030−4.5%/yr |
| Colorectal resection |
Cholecystectomy & appendectomy in every state, and its device makers · Every procedure market in West Virginia · Every state · Compare with Texas
| ≈ 800 |
| – |
| 2026 est. | ≈ 780 | – |
| 46% |
| 2022 | 19 | 1,001 | 50% |
| 2023 | 18 | 856 | 55% |
| 2024 | 19 | 820 | 58% |
| 2025 from claims | – | 798 645–937 | 59% |
| 2026 forecast | – | 780 611–979 | 60% |
| 2027 forecast | – | 765 567–1,011 | 61% |
| 2028 forecast | – | 750 531–1,035 | 62% |
| 2029 forecast | – | 734 499–1,053 | 63% |
| 2030 forecast | – | 719 471–1,067 | 64% |
In 2025, 44% inpatient hospital, 56% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~780 | ~350 | ~430 |
| 2027 · ~760 | ~340 | ~420 |
| 2028 · ~750 | ~340 | ~410 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 55% (56% in 2025), inpatient hospital about 45% (44% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 9,319−5.5%/yr |
| −5.5%/yr |
| 4.3 |
| 1% |
| 10,300 in 2030+1.7%/yr |
| North Carolina | 77 | 4,307−7.3%/yr | −7.3%/yr | 4.5 | 2% | 4,130 in 2030−0.7%/yr |
| Georgia | 78 | 3,999−6.7%/yr | −6.7%/yr | 4.8 | 0% | 4,290 in 2030+1.2%/yr |
| Virginia | 74 | 3,844−4.8%/yr | −4.8%/yr | 3.7 | 1% | 4,110 in 2030+1.1%/yr |
| Tennessee | 81 | 3,433−6.8%/yr | −6.8%/yr | 5.0 | 4% | 3,630 in 2030+0.9%/yr |
| South Carolina | 65 | 2,781−5.5%/yr | −5.5%/yr | 4.2 | 1% | 3,300 in 2030+2.9%/yr |
| Kentucky | 56 | 2,519−8.1%/yr | −8.1%/yr | 5.7 | 1% | 2,490 in 2030−0.2%/yr |
| Maryland | 54 | 2,461−3.8%/yr | −3.8%/yr | 2.8 | 6% | 2,750 in 2030+1.9%/yr |
| Oklahoma | 64 | 2,262−6.3%/yr | −6.3%/yr | 4.8 | 0% | 2,230 in 2030−0.3%/yr |
| Louisiana | 56 | 2,158−8.2%/yr | −8.2%/yr | 5.4 | 3% | 2,120 in 2030−0.3%/yr |
| Alabama | 49 | 2,132−10%/yr | −10%/yr | 5.0 | 4% | 1,870 in 2030−2.2%/yr |
| Arkansas | 59 | 2,014−6.1%/yr | −6.1%/yr | 5.5 | 3% | 1,900 in 2030−0.9%/yr |
| Mississippi | 52 | 1,864−9.9%/yr | −9.9%/yr | 5.1 | 7% | 1,780 in 2030−0.8%/yr |
| Delaware | 14 | 605−4.5%/yr | −4.5%/yr | 3.6 | 0% | 740 in 2030+3.5%/yr |
| District of Columbia | 4 | 315−2.4%/yr | −2.4%/yr | 5.1 | 2% | 340 in 2030+1.3%/yr |
| 0 |
| 265−9.2%/yr |
| −9.2%/yr |
| 1.30.8× |
| 0% |
| 200 in 2030−4.7%/yr |
| Antireflux & hiatal hernia surgery | 2 | 134−13%/yr | −13%/yr | 0.60.8× | 0% | 100 in 2030−5.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Terumo leads with 67% of company spending on these surgeons in 2025, +33 pts on 2024.
In 2025, 5 companies reported engagement with West Virginia’s surgeons worth $3,086 in consulting, speaking, meals and travel tied to these products, about $162 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 33 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.